首页 > 市场调查报告书 > 製药

分子标靶治疗学

BRAF激□抑製剂的全球市场：按药物、适应症、分销渠道、地区规模、份额、前景、机会分析2022-2028

市场调查报告书

商品编码

1085723

BRAF激□抑製剂的全球市场：按药物、适应症、分销渠道、地区规模、份额、前景、机会分析2022-2028

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月21日 | 出版商:

Coherent Market Insights | 英文 158 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球 BRAF 激□抑製剂市场的领先企业专注于获得专利，并有望为新兴市场的製造商创造更多机会。然而，市场的挑战之一是患者的负担。由于成本高昂，患者正在从实际治疗方案转向癌症治疗的替代方案。

本报告研究和分析全球 BRAF 激□抑製剂市场，并提供有关市场驱动因素、抑製剂、市场机会、药物/适应症/分销渠道/区域市场分析和公司概况的信息。

BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.

Market Dynamics

Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.

However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.

Key features of the study:

This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the global BRAF kinase inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.

Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global BRAF Kinase Inhibitors Market, By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
Global BRAF Kinase Inhibitors Market, By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
Global BRAF Kinase Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global BRAF Kinase Inhibitors Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
  - By Country/Region:
- South Africa
- Central Africa
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- F. Hoffmann-La Roche AG*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Novartis International AG
- Pfizer, Inc.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Product Launches
Key Developments
Regulatory Scenario
PEST Analysis
Treatment Evolution
Pipeline Analysis
Reimbursement Scenario

4. Impact of COVID-19 on BRAF Kinase Inhibitors Market

Supply Side And Demand Side Analysis
Overall Impact
Impact on Research and Development

5. Global BRAF Kinase Inhibitors Market, By Drug, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Vemurafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Dabrafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Lifirafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Encorafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global BRAF Kinase Inhibitors Market, By Indication, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Metastatic Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Metastatic Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global BRAF Kinase Inhibitors Market, By Region, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
Europe
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa

9. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

BRAF激□抑製剂的全球市场：按药物、适应症、分销渠道、地区规模、份额、前景、机会分析2022-2028

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第 1 章调查目标/先决条件

第二章市场概述

第三章市场动态、监管和趋势分析

第 4 章 COVID-19 对 BRAF 激□抑製剂市场的影响

第 5 章全球 BRAF 激□抑製剂市场：按药物分类（2017-2028 年（100 万美元））

第 6 章全球 BRAF 激□抑製剂市场：按适应症（2017-2028 年（100 万美元））

第 7 章全球 BRAF 激□抑製剂市场：按分销渠道（2017-2028 年（100 万美元））

第 8 章全球 BRAF 激□抑製剂市场：按地区划分（2017-2028 年（100 万美元））

第9章竞争态势

第10章章节